Antipsychotics and dementia

Abstract

A warning of the FDA has to be accepted as meaning that atypical neuroleptics as a class increase the death rate in elderly patients as long as there is no independent re-analysis yielding different conclusions. At present, a re-analysis is impossible. As this is a frequent adverse reaction, it has to be considered when seeking informed consent. As the FDA suggests a similar risk for typical neuroleptics, this is also true for these drugs. (PsycINFO Database Record (c) 2012 APA, all rights reserved) (journal abstract)